| Meredith Lynn Porter, MD | |
|
6230 Rolling Rd Ste J, Springfield, VA 22152-2326 | |
| (571) 665-6460 | |
| (571) 665-6461 |
| Full Name | Meredith Lynn Porter |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 28 Years |
| Location | 6230 Rolling Rd Ste J, Springfield, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023080827 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 0101056228 (Virginia) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Inova Ucc Llc | 7012385040 | 65 |
| Inova Ucc Llc | 7012385040 | 65 |
News Archive
Following a three-year study using more than 2,800 mice, a University of Missouri researcher was not able to replicate a series of previous studies by another research group investigating the controversial chemical BPA. The MU study is not claiming that BPA is safe, but that the previous series of studies are not reproducible.
People with multiple sclerosis (MS) who underwent a non-invasive form of electrical brain stimulation experienced significant reductions in fatigue, a common and often debilitating symptom of the disease, according to new research from the Multiple Sclerosis Comprehensive Care Center at NYU Langone Health.
St. Jude Children's Research Hospital has launched a freely available website for published research results from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP). The PCGP is the largest effort to date aimed at sequencing the entire genomes of both normal and cancer cells from pediatric cancer patients, comparing differences in the DNA to identify genetic mistakes that lead to childhood cancers.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
For the first time, California's largest nonprofit health insurer has released the salaries of its 10 highest-paid executives in response to a new state law intended to keep health care insurance costs under control.
› Verified 9 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
Following a three-year study using more than 2,800 mice, a University of Missouri researcher was not able to replicate a series of previous studies by another research group investigating the controversial chemical BPA. The MU study is not claiming that BPA is safe, but that the previous series of studies are not reproducible.
People with multiple sclerosis (MS) who underwent a non-invasive form of electrical brain stimulation experienced significant reductions in fatigue, a common and often debilitating symptom of the disease, according to new research from the Multiple Sclerosis Comprehensive Care Center at NYU Langone Health.
St. Jude Children's Research Hospital has launched a freely available website for published research results from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP). The PCGP is the largest effort to date aimed at sequencing the entire genomes of both normal and cancer cells from pediatric cancer patients, comparing differences in the DNA to identify genetic mistakes that lead to childhood cancers.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
For the first time, California's largest nonprofit health insurer has released the salaries of its 10 highest-paid executives in response to a new state law intended to keep health care insurance costs under control.
› Verified 9 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275886418 PECOS PAC ID: 2466351093 Enrollment ID: O20121219000193 |
News Archive
Following a three-year study using more than 2,800 mice, a University of Missouri researcher was not able to replicate a series of previous studies by another research group investigating the controversial chemical BPA. The MU study is not claiming that BPA is safe, but that the previous series of studies are not reproducible.
People with multiple sclerosis (MS) who underwent a non-invasive form of electrical brain stimulation experienced significant reductions in fatigue, a common and often debilitating symptom of the disease, according to new research from the Multiple Sclerosis Comprehensive Care Center at NYU Langone Health.
St. Jude Children's Research Hospital has launched a freely available website for published research results from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP). The PCGP is the largest effort to date aimed at sequencing the entire genomes of both normal and cancer cells from pediatric cancer patients, comparing differences in the DNA to identify genetic mistakes that lead to childhood cancers.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
For the first time, California's largest nonprofit health insurer has released the salaries of its 10 highest-paid executives in response to a new state law intended to keep health care insurance costs under control.
› Verified 9 days ago
| Entity Name | Inova Ucc Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508592114 PECOS PAC ID: 7012385040 Enrollment ID: O20221201001300 |
News Archive
Following a three-year study using more than 2,800 mice, a University of Missouri researcher was not able to replicate a series of previous studies by another research group investigating the controversial chemical BPA. The MU study is not claiming that BPA is safe, but that the previous series of studies are not reproducible.
People with multiple sclerosis (MS) who underwent a non-invasive form of electrical brain stimulation experienced significant reductions in fatigue, a common and often debilitating symptom of the disease, according to new research from the Multiple Sclerosis Comprehensive Care Center at NYU Langone Health.
St. Jude Children's Research Hospital has launched a freely available website for published research results from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP). The PCGP is the largest effort to date aimed at sequencing the entire genomes of both normal and cancer cells from pediatric cancer patients, comparing differences in the DNA to identify genetic mistakes that lead to childhood cancers.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
For the first time, California's largest nonprofit health insurer has released the salaries of its 10 highest-paid executives in response to a new state law intended to keep health care insurance costs under control.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Meredith Lynn Porter, MD 9903 Shady Cove Drive, Fairfax Station, VA 22039-2943 Ph: (202) 415-4847 | Meredith Lynn Porter, MD 6230 Rolling Rd Ste J, Springfield, VA 22152-2326 Ph: (571) 665-6460 |
News Archive
Following a three-year study using more than 2,800 mice, a University of Missouri researcher was not able to replicate a series of previous studies by another research group investigating the controversial chemical BPA. The MU study is not claiming that BPA is safe, but that the previous series of studies are not reproducible.
People with multiple sclerosis (MS) who underwent a non-invasive form of electrical brain stimulation experienced significant reductions in fatigue, a common and often debilitating symptom of the disease, according to new research from the Multiple Sclerosis Comprehensive Care Center at NYU Langone Health.
St. Jude Children's Research Hospital has launched a freely available website for published research results from the St. Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project (PCGP). The PCGP is the largest effort to date aimed at sequencing the entire genomes of both normal and cancer cells from pediatric cancer patients, comparing differences in the DNA to identify genetic mistakes that lead to childhood cancers.
Acorda Therapeutics, Inc. today announced the wholesale acquisition cost (WAC) for AMPYRA™ (dalfampridine) Extended Release Tablets will be $1,056 per 30-day supply (60-count pill bottle), an annual cost of $12,850. AMPYRA was approved on January 22, 2010 by the U.S. Food and Drug Administration (FDA) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA is expected to be available in March 2010.
For the first time, California's largest nonprofit health insurer has released the salaries of its 10 highest-paid executives in response to a new state law intended to keep health care insurance costs under control.
› Verified 9 days ago
Dr. Sonya Nadine Bethel, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7440 Spring Village Dr, Springfield, VA 22150 Phone: 703-923-4644 Fax: 703-923-4625 | |
Dr. Sally R Hayes, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 6230 Rolling Rd Ste Iandj, Springfield, VA 22152 Phone: 571-665-6460 Fax: 571-565-6561 | |
Jeffrey K Nekoba, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7489 Huntsman Blvd, Springfield, VA 22153 Phone: 571-642-1460 Fax: 703-440-1203 | |
Dr. Farah Saeed, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6501 Loisdale Ct, Kaiser Permanente Springfield Medical Center, Springfield, VA 22150 Phone: 703-922-1000 | |
Dr. Priya Jagannathan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6501 Loisdale Ct, Springfield, VA 22150 Phone: 703-944-7662 | |
Mrs. Rebecca Mensah, FNP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 8020 Pohick Rd, Springfield, VA 22153 Phone: 571-484-0443 |